Latest Breaking News On - Nabil abadir - Page 4 : comparemela.com

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,.

Amarin Corp. (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress

Amarin Corporation plc: Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

- New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression - Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism

Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events

— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — Data Further Advances Understanding of VASCEPA/VAZKEPA. | May 12, 2023

Amarin Corp. to Present New Data Evaluating Vascept/Vazkepa (Icosapent Ethyl) at ACC23/WCC

Presentations on Additional REDUCE-IT Sub-Population, In-Vitro Data on EPA to Be Featured at the Congress